Aditi Bagchi, MD, PhD, St. Jude Department of Oncology, and international collaborators conducted a meta-analysis to identify prognostic factors in infant-type hemispheric glioma (IHG), providing insights to guide safer and more effective treatment strategies.
Clinician-scientists at St. Jude Children’s Research Hospital and collaborators have conducted the largest study of infant-type hemispheric glioma (IHG) ever reported, uncovering key factors that could be used to guide treatment strategies for this rare pediatric brain tumor. Combining new and previously published clinical and molecular data, the study demonstrated that the prognosis of these patients is dependent on safe primary surgical resection, leading to complete removal of the tumor. The findings were published today in Neuro-Oncology.
IHGs are aggressive brain tumors that occur during early infancy, usually between 0 and 12 months of age. They are often very large at the time of diagnosis, sometimes occupying over 50% of the cerebral volume. Molecularly, these large tumors are driven by unique alterations in receptor tyrosine kinase (RTK) that lead to uncontrolled growth and proliferation of cells. Historical publications show better overall survival of IHG in comparison to high-grade gliomas commonly diagnosed in older children and adults. Despite better overall survival rates, primary treatment failure rates and treatment-associated morbidity are high. Clinical research in the field has been stymied by the rarity of IHG, which has made large-scale studies of factors influencing clinical outcomes nearly impossible.
“IHGs are often misinterpreted as incurable at presentation, especially because of their large size and hemorrhagic characteristics on diagnostic imaging, but that is not true,” explained co-first and co-corresponding author Aditi Bagchi, MD, PhD, St. Jude Department of Oncology, Division of Neuro-Oncology. “With precise and timely management at diagnosis by an experienced team of pediatric neurosurgeons and neuro-oncologists, these tumors can be treated successfully.”
Meta-analysis reveals factors that affect clinical outcomes
To better understand the predictors of clinical outcome for IHG, Bagchi and her colleagues gathered clinical cases from 20 institutions across 11 countries. The researchers performed a meta-analysis using data from 164 cases of IHG, creating the largest dataset ever reported for this tumor type.
“An analysis of this size for IHG has never been published before,” said Bagchi. “Because this tumor is so rare, no single center sees hundreds of cases, so pooling data worldwide was essential.”
The study identified two major factors that improve survival for children with IHG. First, achieving a complete surgical resection is critical for long-term outcomes. Second, surgery should be followed by cancer-directed adjuvant treatment to improve outcomes further. These findings lay the foundation for successful treatment; however, the study also showed that early surgery in infants was fraught with risks of bleeding and early oncologic death.
The study reports that making neurosurgical decisions at the time of diagnosis is often difficult, not only because IHGs tend to be large and prone to bleeding, but also due to the patients’ extremely young age and low body weight.
“We need strategies that minimize surgical morbidity while maintaining the success of complete resection,” emphasized Bagchi.
By sharing these insights, the authors hope to guide future treatment strategies and inspire continued collaboration to improve care for children affected by IHG.
“What makes this study truly remarkable is the level of international collaboration,” said Bagchi. “We are incredibly grateful for our collaborators, especially the University of Geneva. This study would not have been possible without this combined effort.”
Bagchi is working to build on the insights from this meta-analysis to launch a clinical trial testing strategies that could make primary surgery safer and more effective for IHG using molecularly directed treatment approaches. These efforts serve as an important bridge between research and practice and lay the foundation for improved treatment of this rare tumor.
Authors and funding
The study’s other co-corresponding author is Andre von Bueren, and the other co-first author is Lara Chavaz, both of the University of Geneva. The study’s other authors are Sandeep Dhanda, Amar Gajjar, Giles Robinson, Matthew Clarke, Alan Mackay, Chris Jones, Jason Chiang, Xin Zhou and Paul Klimo, of St. Jude; Fabienne Toutain, University of Geneva; Stefan Pfister, Dominik Sturm and David Jones, Heidelberg University Hospital and Hopp Children’s Cancer Center Heidelberg (KiTZ), Germany; Torsten Pietsch, Gerrit Gielen and Andreas Waha, University of Bonn; Michael Karremann, University Medical Center Mannheim, Heidelberg University; Martin Benesch, Thomas Perwein and Gunther Nussbaumer, Medical University of Graz; Christof Kramm, University Medical Center Göttingen; Maura Massimino and Veronica Biassoni, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano; Maria Vinci and Angela Mastronuzzi, Bambino Gesù Children’s Hospital IRCCS; Dannis van Vuurden, Princess Máxima Center for Pediatric Oncology; Sophie Veldhuijzen van Zanten, Erasmus MC; Ana Guerreiro Stucklin, University Children’s Hospital Zurich; Uri Tabori, Cynthia Hawkins and Scott Ryall, The Hospital for Sick Children, Toronto; Andrés Morales La Madrid, Hospital Sant Joan de Déu; Alvaro Lassaletta, Hospital Infantil Universitario Niño Jesús; Simon Bailey, Royal Victoria Infirmary Queen, Newcastle upon Tyne; Darren Hargrave, Great Ormond Street Hospital for Children; Moatasem El-Ayadi, Cairo University; Bruna Mançano and Rui Reis, Barretos Cancer Hospital; Christian Hagel, University Medical Center Hamburg-Eppendorf; Hamza Gorsi, Children’s Hospital of Michigan; Nicolas Silvestrini, Geneva University Hospitals and Faculty of Medicine; Ahmed Gilani, Children’s Hospital Colorado; and Ludmilla Papusha, Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology.
The study was supported by grants from the CANSEARCH Foundation, National Cancer Institute (P30CA021765), the CRIS Cancer Foundation, the NIHR Great Ormond Street Hospital Biomedical Research Centre, an Else Kröner Excellence Fellowship and the American Lebanese Syrian Associated Charities (ALSAC), the fundraising and awareness organization of St. Jude.
St. Jude Children's Research Hospital
St. Jude Children’s Research Hospital is leading the way the world understands, treats, and cures childhood catastrophic diseases. As the only National Cancer Institute-designated Comprehensive Cancer Center devoted solely to children, St. Jude advances groundbreaking research and shares its discoveries worldwide to accelerate progress in pediatric medicine. Treatments developed at St. Jude have helped increase overall childhood cancer survival rates from 20% to 80% since the hospital opened more than 60 years ago. Through collaboration and innovation, St. Jude is working to ensure that children everywhere have access to the best possible care. To learn more, visit stjude.org, read St. Jude Progress, a digital magazine, and follow St. Jude on social media at @stjuderesearch.